• Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infection
  • HBeAg- cohort sample size increased to optimize powering; futility criteria not met
  • Study drugs were well-tolerated by participants
  • Topline data expected in 2027, guidance remains unchanged